Tumor suppressor genes and the immune system are critical players in inhibiting cancer initiation and/or progression. However, little is known about whether a tumor suppressor gene can function through both immune-dependent and -independent mechanisms. Retinoic acid receptor responder 2 (RARRES2) is transcriptionally downregulated in multiple cancer types. Previous studies suggested that it can serve as an immune-dependent tumor suppressor by acting as a chemoattractant to recruit anticancer immune cells expressing its receptor, the chemerin chemokine receptor 1 (CMKLR1), to sites of tumor. In this study, we investigated the role of RARRES2 in adrenocortical carcinoma (ACC), a rare lethal malignancy in which aberrant Wnt/β-catenin signaling is frequently detected. We show that RARRES2 expression is downregulated in ACC as compared with normal and benign adrenocortical tissues, which is a result of CpG hypermethylation. Despite minimal CMKLR1 expression and lack of phenotypic tumor-suppressive effect with exogenous RARRES2 treatment, RARRES2 overexpression in ACC cell lines not only reduced cell proliferation, cell invasion and tumorigenicity in vitro, but also inhibited tumor growth in vivo in two immunodeficient mouse xenograft models. Mechanistically, RARRES2 overexpression in ACC cells inhibited Wnt/β-catenin pathway activity by promoting β-catenin phosphorylation and degradation, it also inhibited the phosphorylation of p38 mitogen-activated protein kinase. Thus our study identifies RARRES2 as a novel tumor suppressor for ACC, which can function through an immune-independent mechanism.
INTRODUCTION
Cancer initiation and progression are the consequence of cumulative genetic and epigenetic alterations. Such alterations, especially in proto-oncogenes, will disrupt tissue homeostasis and lead to tumor formation. 1 The human body has comprehensive strategies to combat cancer initiation and/or progression. On one hand, numerous tumor suppressor genes are in place to counteract the tumorigenicity resulting from oncogenic activation. 1 On the other hand, the immune system also has a role in tumor destruction and preventing cancer progression. 2 However, little is known about whether a tumor suppressor gene can function through both immune-dependent and -independent antitumor mechanisms.
Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with an estimated incidence of 0.7-2.0 cases per million people per year and a 5-year overall survival rate ranging from 32 to 47%. [3] [4] [5] Various genetic alterations have been identified in ACC, which might lead to the pathogenesis of ACC, among which, one of the most frequently observed event is the constitutive activation of the Wnt/β-catenin signaling pathway. 6 Although lots of studies have been done to identify oncogenic mechanisms of ACC, little is known about whether there are any tumor suppressor genes that could counteract the development of ACC.
Retinoic acid receptor responder protein 2 (RARRES2), also known as chemerin, was first identified as a secreted ligand for the orphan G protein-coupled receptor chemokine-like receptor 1 (CMKLR1). 7, 8 RARRES2 can function as a chemoattractant by recruiting immune cells expressing CMKLR1 to lymphoid organs and sites of tissue injury, thus having an important role in immune response. 7, [9] [10] [11] Recent data also support the idea that RARRES2 can function as an adipokine, which regulates adipocyte development and metabolism by signaling through CMKLR1. 12, 13 Growing evidence suggest that RARRES2 might also have a role in cancer development. The RARRES2 gene has been found to be transcriptionally downregulated in ACC, skin squamous cell carcinoma, melanoma, human hepatocellular carcinoma, and in lung, breast, colon and metastatic prostate cancers as compared with normal and/or benign tumors in each organ. [14] [15] [16] [17] [18] [19] Recent studies suggest that RARRES2's function in cancer is associated with its chemoattractant ability. For example, in human hepatocellular carcinoma, reduced RARRES2 protein expression in tumor tissues was associated with lower infiltration of dendritic cells and natural killer cells; 17 whereas in melanoma, RARRES2 was shown to have an indirect role in tumor suppression by recruiting CMKLR1-expressing natural killer cells to tumor sites in order to carry out an antitumor effect. 18 In this study, we provide evidence that RARRES2 has a direct tumor-suppressive effect that does not require immune cell recruitment to be executed. We showed that RARRES2 was downregulated in ACCs, which was due to gene hypermethylation. RARRES2 overexpression in vitro led to reduced cell proliferation, cell invasion and tumorigenicity. Using mouse xenografts of ACC cell lines with stable RARRES2 overexpression in two immunodeficient mouse models, we showed that RARRES2 expression alone was sufficient for suppressing tumor growth. Mechanistically, RARRES2 overexpression promoted the phosphorylation and degradation of β-catenin, which is associated with reduced Wnt/β-catenin pathway activity; it also inhibited the phosphorylation of p38 mitogenactivated protein kinase (MAPK). Thus, we present the first evidence that RARRES2 can function as a tumor suppressor in ACC through a novel immune-independent mechanism.
RESULTS
CpG hypermethylation suppresses RARRES2 expression in ACC In our previous genome-wide methylation profiling study in adrenocortical tissues, 19 we found that RARRES2 was significantly hypermethylated in ACCs as compared with benign adrenocortical tumors and normal adrenocortical samples. Significant hypermethylation was detected at five CpG sites (cg11327659, cg 13722127, cg19310340, cg21521758 and cg274550017), three of which were located in the body of the gene, whereas the other two were located in the 5´untranslated region (Figure 1a) . The methylation at the CpG site, cg11327659, was validated by pyrosequencing in 8 ACC tissues and 42 benign tissues (Figure 1b) . To further validate that methylation did occur at these five sites, and to assess their impact on RARRES2 gene expression, we treated three ACC cell lines (NCI-H295R [H295R], SW13 and BD140A) and HEK293 cells with decitabine, a DNA methyltransferase inhibitor. In all four cell lines, decitabine treatment led to a significant reduction in methylation at all five CpG sites (Figure 1c) , with dose-dependent increases in RARRES2 gene expression levels (Figure 1d ). These findings suggest that, in ACC, RARRES2 expression is suppressed by CpG hypermethylation, a common mechanism of gene silencing in cancer.
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RARRES2 expression is significantly downregulated in ACCs To determine whether RARRES2 is differentially expressed in adrenocortical tissues, TaqMan real-time quantitative PCR (qPCR) was performed in 21 normal adrenocortical tissues, 68 benign adrenocortical tumors and 26 ACCs. RARRES2 expression was significantly downregulated in ACCs as compared with benign and normal tissues. It was also significantly downregulated in benign tumors as compared with normal tissues (Figure 2a) . Further, we analyzed RARRES2 gene expression in two publically available adrenocortical databases (NCBI-GEO data set accession no. GSE10927 (ref. 21) and European Bioinformatics Institute (EMBL-EBI) accession no. E-TABM-311 (ref. 22) ) and found lower RARRES2 expression in ACCs (Figures 2b and c) . To examine RARRES2 protein expression in adrenocortical tissues, immunohistochemical (IHC) staining for RARRES2 was performed in adrenocortical tissue sections from 10 normal, 56 benign and 19 ACC samples and total signal intensity for each slide was scored. Compared with normal adrenocortical tissues, RARRES2 protein expression was Figure 1 . Epigenetic CpG hypermethylation suppresses RARRES2 expression in adrenocortical tumors. (a) Five CpG sites in RARRES2 were significantly methylated in ACCs as compared with benign and normal adrenocortical tissue samples. ACC, n = 8; benign, n = 47; normal, n = 19. Mvalue, the log2 ratio of the intensities of methylated probe versus unmethylated probe. Beta-value, the ratio of the methylated probe intensity and the overall (methylated and unmethylated) probe intensity. (b) Pyrosequencing validation of the methylation status for the CpG site cg11327659. ACC, n = 8; benign, n = 42. *, Po0.0005. (c) Pyrosequencing results revealed that decitabine treatment significantly reduced RARRES2 methylation in the five targeted CpG sites in cultured H295R, SW13, BD140A and HEK293 cells. (d) Decitabine treatment increases RARRES2 gene expression in cultured H295R, SW13, BD140A and HEK293 cells as detected by TaqMan qPCR. *, Po0.05; **, Po0.01; ***, Po0.005. (c) and (d) Owing to the longer cell doubling time, H295R were treated for 144 h, whereas the other cell lines were treated for 72 h. DAC, decitabine.
significantly lower in benign tumors, and even lower in ACC samples, which is consistent with the mRNA expression profiles we observed (Figures 2d and e) . In 9 normal, 48 benign and 15 ACC tissue samples with paired gene expression data by qPCR and protein expression data by IHC, a correlation analysis was performed. RARRES2 mRNA expression was significantly correlated with protein expression in these adrenocortical tissue samples (r = 0.3194, P = 0.0062; Figure 2f ). RARRES2 overexpression inhibits cell proliferation, cell invasion and tumorigenesis in Vitro As ACCs had significantly reduced RARRES2 expression, and the endogenous gene expression levels of RARRES2 and CMKLR1 were barely detectable in all the cell lines we tested, including three ACC cell lines (Figure 3a) , we decided to overexpress RARRES2 to assess its physiological function. After transient transfection, RARRES2 expression was strongest and most sustained in HEK293 cells, moderate in H295R cells, and weakest in SW13 cells (Figure 3b) . The RARRES2 protein level was not detected in BD140A cells after transfection (data not shown). Transient RARRES2 overexpression led to significantly reduced cell proliferation in HEK293 cells, and reduced cell invasion in H295R cells and HEK293 cells, but had no significant effect on cell migration (Figures 3c-e) .
In order to test the long-term effect of RARRES2 expression in ACC cells, we generated stable polyclonal ACC cell lines expressing either an empty vector or RARRES2. One empty vector cell line and two independently derived RARRES2-expressing cell Figure 2 . RARRES2 expression is significantly downregulated in adrenocortical carcinomas. (a) TaqMan real-time qPCR result confirms RARRES2 downregulation in ACCs in our cohort of adrenocortical tissue samples. Normal, n = 21; Benign, n = 68; ACC, n = 26. *, P o0.05; **, P o0.0005; ***, Po 0.0001. (b) RARRES2 expression in publicly available microarray data from the GEO database (accession no. GSE10927). ACA, adrenocortical adenoma. Normal, n = 10; ACA, n = 22; ACC, n = 33. *, Po0.05; **, P o0.0001. (c) RARRES2 expression in publicly available microarray data from EMBL-EBI (accession no. E-TABM-311). Normal, n = 4; ACA, n = 58; ACC, n = 34. *, P o0.05; **, Po0.0001; ns, not significant. (a-c), Individual tissue samples were represented by dots. Long horizontal lines represent the means; short horizontal lines represent the s.d. (d) Representative IHC staining images for RARRES2 in adrenocortical tissues. Scale bars, 100 μm. Inset, zoom in images. (e) Quantification of RARRES2 staining intensity in adrenocortical tissues. Normal, n = 10; Benign, n = 56; ACC, n = 19. Intensity scores: 0, no staining; 1, weak staining; 2, moderate staining, 3, strong staining. Total staining intensity = ∑ (intensity scores x percent positivity). *, P o0.005; **, P o0.0005; ***, Po0.0001. (f) Correlation between tissue RARRES2 mRNA expression level, measured by Taqman qPCR as % gene expression relative to GAPDH and RARRES2 protein level, as scored from IHC. r, correlation coefficient. Paired RNA and tissue slides from 9 normal, 48 benign and 15 ACC tissues were analyzed. lines, namely, Line-1 and Line-2, were tested. Compared with the vector cell line, RARRES2-overexpressing Line-1, but not Line-2, showed significant growth inhibition (Figure 4a) . Interestingly, Line-1 had a consistently higher expression of RARRES2 than Line-2 ( Figure 4b) ; thus, the growth suppression observed was RARRES2-dose-dependent. Importantly, both RARRES2-overexpressing cell lines showed markedly inhibited tumorigenicity as exemplified by reduced colony formation in clonogenic assays ( Figure 4c ) and anchorage-independent growth in soft agar colony formation assays (Figure 4d ), and the extent of inhibition was also correlated with the expression level of RARRES2. Extracellular RARRES2 does not exhibit any phenotypic effect As RARRES2 is known as a secreted protein, and most of its known function is thought to be through the binding of its receptor, CMKLR1, we wonder if residual CMKLR1 expression in these cells could still mediate the growth-suppressive effect we observed in vitro. To test this hypothesis, we examined whether exogenous addition of recombinant RARRES2 protein would have any functional impact in vitro. Recombinant human chemerin was added to the culture media of H295R, SW13 and HEK293 cells at various physiological concentrations. However, we did not observe any significant changes in cell proliferation or cell invasion/migration (Supplementary Figure S1 ).
RARRES2 overexpression promotes beta-catenin phosphorylation and degradation, and inhibits p38 MAPK phosphorylation To identify the mechanism behind the tumor-suppressive effect of RARRES2, we performed a phosphokinase array in the stable cell lines. RARRES2 overexpression led to significantly reduced total β-catenin levels and phospho-p38 MAPK levels ( Figure 5a ). These results were further confirmed by western blot analysis ( Figure 5b ).
The reduction in β-catenin protein levels was not due to a decrease in gene expression, because TaqMan real-time qPCR of the stable cell lines revealed no significant changes in β-catenin transcription levels when RARRES2 was overexpressed ( Figure 5c ). Thus, these results suggested that β-catenin downregulation may be due to posttranslational mechanism(s). To test whether the reduction in total β-catenin is caused by phosphorylation and subsequent proteasome-mediated degradation, the cells were treated with MG132, a known proteasome inhibitor. 23 Compared with the control dimethyl sulfoxide-treated cells, which exhibited a minimally detectable phospho-β-catenin signal, MG132 treatment successfully blocked proteasome-mediated degradation, thus allowing the phosphorylated β-catenin to be detected ( Figure 5d ). Compared with the vector control, RARRES2 overexpression promoted β-catenin phosphorylation at Ser33/Ser37/ Thr41, leading to increased proteasome-mediated degradation, as a result, a reduced total β-catenin level. To observe this effect in situ, immunofluorescent staining was performed in H295R cells transiently transfected with either an empty vector or a RARRES2 overexpression construct, so that cells with different levels of RARRES2 expression could be compared. RARRES2 expression was mostly cytoplasmic with some membrane localization. Overexpression of RARRES2 led to uniform reduction of total β-catenin levels in the cells (Figure 5e ).
To determine whether the reduced total β-catenin level resulting from RARRES2 overexpression could affect the activity of the Wnt/β-catenin pathway, a T-cell factor/lymphoid enhancer factor (TCF/LEF) luciferase reporter assay was performed in the stable cell lines. Consistent with total β-catenin levels in the cell lines, the TCF/LEF reporter activity was also reduced in the RARRES2-overexpressing cell lines as compared with the vector cell line (Figure 5f ). We further performed cell line mutational analysis in all ACC cell lines in order to examine if there are any mutations in Wnt/β-catenin pathway-related genes that could affect the activity of this pathway. Only H295R cells harbored a heterozygous S45P mutation in CTNNB1 (Supplementary Table 1) .
To determine whether the phosphorylation change in p38 MAPK is physiologically relevant in ACC, IHC staining for phosphop38 was performed. Nuclear localized phospho-p38 signal was detected in 21 of 30 ACC samples tested (70%; Figure 5g) . The relative expression level of phospho-p38 was further studied in a subset of adrenocortical tissue samples containing eight normal, eight benign and eight local recurrent ACC tissues. Interestingly, phospho-p38 to p38 ratio was significantly higher in ACC as compared with normal and benign tissues (Figure 5h ).
Since RARRES2 overexpression led to reduced cellular invasion, we also tested if RARRES2 expression would affect extracellular matrix protein levels, which are major protein mediators of cellular invasion. The expression of five common cell adhesion molecules (fibronectin, collagen I, collagen IV, laminin I, fibrinogen) were not detected in H295R cells regardless of RARRES2 expression in an extracellular matrix cell adhesion array (data not shown). However, we did find that the level of N-cadherin decreased significantly when RARRES2 was overexpressed (Figure 5b ).
RARRES2 overexpression suppresses tumor growth in mouse xenograft models To examine the function of RARRES2 in vivo, we performed xenograft studies using two different immunodeficient mouse models: athymic nude and NOD Scid gamma (NSG) mice. Stable H295R cells that were expressing either an empty vector or RARRES2 (Line-1) were injected subcutaneously into both flanks of the mice. In both models, RARRES2 overexpression significantly suppressed tumor growth (Supplementary Figure S2a Figure S2e) . The NSG mouse models are more immunodeficient because they have no mature T cells, B cells and natural killer cells and are macrophage and dendritic celldefective; 24 ,25 nonetheless, we tested mouse CMKLR1 expression in tumors isolated from these mice and found no difference between the groups (Figure 6f) . Consistent with the observation in vitro, NSG mice tumors with RARRES2 overexpression showed reduced total β-catenin and reduced phospho-p38 MAPK levels (Figure 6g ). 
DISCUSSION
In this study, we provide evidence that RARRES2 is downregulated in ACC as a result of CpG hypermethylation. We also show that RARRES2 can function as a tumor suppressor independently of its chemoattractive ability. RARRES2 overexpression not only led to reduced cell proliferation, cell invasion and reduced Figure 6 . RARRES2 overexpression inhibits tumor growth in an NSG mice xenograft model. (a) The tumor growth curve in NSG mice. RARRES2 overexpression resulted in a significant growth inhibition as compared with the vector group starting from 3 weeks after xenograft. Each group contains 7 mice/14 xenografts, but in the RARRES2 group, one xenograft never developed a measurable tumor, thus was excluded. Data were presented as mean ± s.e.m. *, P o0.0001, **, P o0.005, ***, P o0.05. and (f), Vector, n = 14; RARRES2, n = 13. (g) RARRES2 expression was associated with reduced p-p38 and total β-catenin levels. Left panel, western blotting performed in seven tumors from the vector group, and six tumors from the RARRES2 group. Arrow head points to the p-p38 band. Right panel, quantification of western blot images. *, P o0.01; **, P o0.05. tumorigenicity in vitro, but also markedly inhibited tumor growth in vivo in two immunodeficient mouse models.
We studied the mechanisms by which RARRES2 may have the phenotypic effects we observed in vitro and in vivo. We found that RARRES2 overexpression lead to reduced total β-catenin levels in H295R cells in a RARRES2-dose-dependent manner. This is consistent with a recent study reported by Salomon et al., as RARRES2 overexpression recapitulates many of the phenotypes exhibited by loss of β-catenin in the H295R cells, such as reduced cell proliferation and reduced anchorage-independent growth. 26 We then examined the cause of β-catenin reduction and the potential impact on the Wnt/β-catenin pathway. In the canonical Wnt/β-catenin pathway, when Wnt is absent, cytoplasmic β-catenin is sequestered within a complex that contains the scaffolding protein axin, the tumor suppressor adenomatous polyposis coli, glycogen synthesis kinase 3 and casein kinase 1. 27 Casein kinase 1 phosphorylates β-catenin at Ser45, which primes it for the subsequent phosphorylation at Thr41, Ser37 and Ser33 by glycogen synthesis kinase 3. 28 The E3 ubiquitin ligase β-Trcp recognizes the phosphorylated β-catenin and targets it for proteasome degradation. When Wnt is present, the axin-mediated β-catenin phosphorylation and degradation is disrupted, allowing β-catenin to enter and accumulate in the nucleus, where it serves as a transcriptional co-activator for the TCF/LEF family of transcription factors and turns on Wnt-responsive target genes.
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H295R cells harbor a heterozygous β-catenin mutation on the casein kinase 1 phosphorylation site (Ser45Pro), resulting in constitutive TCF-dependent transcription. 29 By mutation analysis of the cell lines used in the current study, we confirmed the existence of such mutation in H295R cells. We also showed that RARRES2 overexpression could enhance β-catenin phosphorylation at Ser33/Ser37/Thr41, thus promoting the degradation of the β-catenin protein. Using a TCF/LEF luciferase reporter assay, we confirmed that loss of total β-catenin levels reflected the reduction in Wnt/β-catenin pathway activity. These results are particularly significant as the activation of the Wnt/β-catenin signaling pathway is observed in 54% of adrenocortical tumors, and β-catenin activation is associated with higher tumor grades, decreased overall survival and decreased disease-free survival in patients with ACC. 29, 30 Wnt/β-catenin pathway activation has been observed in both benign ACAs and ACCs; 29 however, it is unknown why the same pathway alteration(s) results in different benign and malignant tumors. We showed that RARRES2 is downregulated in ACCs as compared with ACAs and normal adrenocortical tissues. Through pyrosequencing, we also confirmed that epigenetic CpG hypermethylation is a cause of RARRES2 downregulation in ACCs. As RARRES2 can promote β-catenin phosphorylation and degradation, thus affecting Wnt/β-catenin pathway activity, reduced RARRES2 expression in ACCs may be a contributing factor for cancer initiation in ACAs.
The p38 MAPK signaling pathway has been shown to play dual roles in human cancers. Depending on the context, it can be proapoptotic, acting as a tumor suppressor by promoting cell death and inhibiting malignant transformation; it can also be protumorigenic, acting as an oncogene by promoting cancer cell survival, proliferation, invasion/migration and regulating cancer metabolism. 31, 32 Activation of p38 signaling is positively correlated with bad prognosis in cancers. 32 In our study, we found that RARRES2 overexpression led to reduced phosphorylation of p38 both in vitro and in vivo. IHC staining in ACCs revealed that phospho-p38 signal is present in most tumor samples. We also found that phospho-p38/total p38 levels were significantly higher in ACC as compared with normal and benign samples. To our knowledge, our data present the first evidence that the p38 MAPK pathway might be physiologically relevant to the development of ACCs. The increase in phospho-p38/total p38 levels observed in ACC might be associated with decreased RARRES2 expression.
Currently, RARRES2 is recognized as a secreted protein that can bind to three known receptors, including CMKLR1, chemokine(C-C motif) receptor-like 2 and G protein-coupled receptor 1. 7, 33, 34 CMKLR1 is the only functional receptor that mediates RARRES2's known function in inflammation, obesity and immune-dependent tumor suppression. 8, 18, 35 However, in our study, we showed that RARRES2 overexpression alone can lead to reduced tumorgenicity both in vitro and in vivo in two immunodeficient mouse models. These experiments provided evidence that RARRES2 can function as an immune-independent tumor suppressor. It is unclear whether this immune-independent tumor-suppressive role of RARRES2 functions through CMKLR1 since endogenous CMKLR1 gene expression levels were barely detectable in all the cell lines we tested, and no significant phenotypic effect was observed when the cells was treated with commercially available recombinant RARRES2 protein. There are several possible reasons that the commercially available recombinant RARRES2 fails to elicit the same phenotype as the overexpressed protein. First, the half-life of the recombinant protein might be too short to induce a phenotype. Second, it is Escherichia coli-derived, which might have different posttranslational modification than those produced by human cells, which might affect its activity. Third. RARRES2 is translated as a 163 amino-acid proprotein, 7 whereas the commercially available recombinant protein is a cleaved form that contains only amino acids 21-157. Although this cleaved protein is active in inducing chemotaxis of immune cells through CMKLR1, it is not known whether the cleaved form will be enough to induce the tumor-suppressive effect found in our study. It is possible that RARRES2 does not need to function through a receptor to carry out its tumor-suppressive function. In fact, from IHC in human tissue samples and immunofluorescence staining in RARRES2-overexpessing cells, we observed that RARRES2 is mainly located in the cytoplasm, which suggests that it might have other function as a cytosolic protein.
Whether RARRES2 exhibits a direct or indirect tumorsuppressive role might be tissue specific. It is also possible that the immune-dependent and -independent tumor-suppressive roles of RARRES2 are not mutually exclusive. However, the downregulation of RARRES2 gene expression was observed in multiple human malignancies such as skin squamous cell carcinoma, hepatocellular carcinoma, and in lung, breast and colon cancers. [16] [17] [18] Interestingly, abnormal Wnt/β-catenin activity has also been observed in human squamous cell carcinoma, hepatocellular carcinoma, breast cancers and lung cancers. 36 In breast and lung cancers, Wnt signaling is hyperactive despite rare pathway mutations. 36 In lung cancers and high-grade colon cancers, aberrant activation of p38 signaling has been reported. 37, 38 These findings prompt us to speculate that the direct tumor-suppressive effect of RARRES2 might not be limited to ACCs. In fact, transient RARRES2 overexpression in HEK293 cells showed reduction in cell proliferation and invasion, which supports this speculation. It would be interesting to test the role of RARRES2 in the other cancers.
In summary, we present, for the first time, evidence that RARRES2 can function as a tumor suppressor in ACC in an immune-independent manner. RARRES2 is a unique tumor suppressor that possesses both immune-dependent and -independent tumor-suppressive abilities.
MATERIALS AND METHODS

Patient samples
Human adrenocortical tissue samples were collected according to an institutional review board-approved clinical protocol after written informed consent was obtained (NCT01005654 and NCT01348698).
Cell lines, transfection and recombinant protein treatment Human ACC cell lines H295R and SW13 were purchased from ATCC (Rockville, MD, USA), cultured in Dulbecco's Modified Eagle Medium supplemented with 1% insulin transferrin selenium and 2.5% NuSerum I (Corning, Bedford, MA), and authenticated by short tandem repeat profiling. The BD140A ACC cell line was kindly provided by Drs Kimberly Bussey and Michael Demeure (TGen, Pheonix, AZ, USA), and was cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 1% L-glutamate (Life Technologies, Grand Island, NY). Human embryonic kidney cell line HEK293 was cultured in Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum (Sigma-Aldrich, St Louis, MO, USA) and 1% penicillinstreptomycin. All cell lines were maintained in a standard humidified incubator with 5% CO 2 at 37°C. All cell lines had been recently authenticated by short tandem repeat profiling and tested for mycoplasma contamination.
For transient transfection, the RARRES2 plasmid (SC118329, pCMV-XL5-RARRES2) and empty vector (pCMV-XL5) were obtained from Origene (Rockville, MD, USA). Mirus TransIT-2020 (Mirus Bio LLC, Madison, WI, USA) was used for transfecting ACC cell lines, whereas X-tremeGENE HP (Roche, Indianapolis, IN, USA) was used for transfecting HEK293. To establish the RARRES2-overexpressing stable cell lines, RARRES2 cDNA from pCMV-XL5-RARRES2 was cloned into the pcDNA4/Myc-His A vector (Life Technologies) to generate pcDNA4-RARRES2 so that only the un-tagged protein was expressed. pcDNA4-RARRES2 was linearized with BglII (New England Biolabs, Ipswich, MA, USA) and was transfected into H295R cells in six-well plates. Three days after transfection, the selection marker Zeocin (Life Technologies) was added to the cell culture medium at 1 μg/ml. The medium with Zeocin was changed twice a week until the drug-resistant clones grew. Cells from one six-well were pooled as one polyclonal line and were maintained in selection medium. A stable cell line established by transfecting H295R cell line with a BglII-linearized pcDNA4/Myc-His A vector was used as the vector control.
Recombinant human chemerin protein was obtained from R&D systems (Minneapolis, MN, USA, 2324-CM-025), and reconstituted according to the manufacturer's protocol. 
Immunohistochemistry
Tissue-section slides were de-paraffinized in xylene and rehydrated in ethanol, followed by antigen retrieval with 10% citrate buffer (pH 6.0) in a pressure cooker for 10 min at 120°C. Slides were incubated with the primary antibody at 4°C overnight. For RARRES2 staining, tissues were fixed with 10% formalin and embedded in paraffin. Anti-chemerin antibody (Abcam, Cambridge, MA, USA, ab72965) was used at 12.5 μg/ ml. Immunostaining was performed using the Dako Envison+System-HRP (horseradish peroxidase) (DAB) for mouse primary antibodies (Dako, Carpinteria, CA, USA). IHC slides were scored using the formula Total staining intensity = ∑ (intensity scores QUOTE percent positivity), where intensity score 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. Interpreter of the IHC was blind to the diagnosis and gene expression levels accessed by real-time qPCR. For phospho-p38 staining, primary antibody used was phospho-p38 (Thr180/Tyr182) antibody (1:800, Cell Signaling, Danvers, MA, USA, #4511). Immunostaining was performed by detection with SignalStain Boost IHC detection reagents (HRP, Cell signaling, rabbit #8114), followed by staining with Vector DAB peroxidase (HRP) substrate kit (Vector laboratories, Burlingame, CA, USA, SK-4100). Hematoxylin (Sigma-Aldrich) was used for counterstaining.
Cell Proliferation, invasion and migration
Cell proliferation experiments were performed using CyQUANT cell proliferation assays (Life Technologies) according to the manufacturer's protocol. For transiently transfected cells, the cells were first transfected in six-well plate, trypsinized 24 h later, counted and then seeded at least in quadruplicate on 96-well black plates to monitor growth. Absorbance at 485 nm/538 nm was determined using a 96-well fluorescence microplate reader SpectraMax M5 (Molecular Devices, Sunnyvale, CA, USA). H295R cells were seeded at 8000 cells/well, HEK293 cells at 3000 cells/well and SW13 at 6000 cells/well. Four independent experiments were performed for each cell line.
Cell invasion and migration assays were performed using the BioCoat Matrigel Invasion chamber and control chamber (Corning, Corning, NY, USA) according to the manufacturer's protocol. Cells were seeded in duplicate at 1 × 10 5 cells/insert. Transiently transfected cells were first transfected in six-well plate, then trypsinized and seeded at 24 h after transfection. Stably transfected cells were seeded directly. The plates were then incubated at 37°C to allow for cell invasion/migration. ACC cells were incubated for 44 h, whereas HEK293 cells were incubated for 22 h. Inserts were then fixed and stained with Diff-Quik (Dade Behring, Newark, NJ, USA). Images of the stained inserts were taken under a light microscope and quantified using Image J software (National Institutes of Health, Bethesda, MD, USA). For invasion, the cell number in the entire insert was counted. For migration, the cell number in four random fields of one insert was counted and summed. For each experiment, invasion/migration was measured as the ratio of total invaded/migrated RARRES2-overexpressing cells to cells expressing the empty vector. The final figure represents collective results from four independent experiments for the transiently transfected cells and three independent experiments for the stably transfected cells. Paired t-test was used to compare difference between each group. Clonogenic assay and crystal violet staining A solution of 0.1% Gelatin (Sigma-Aldrich) in phosphate-buffered saline was used to coat six-well plates and was discarded after half an hour. Stable H295R cells were seeded at 5000 cells/well and cultured for 3 weeks until the colonies reached optimal size. After discarding the cell culture medium, the cells were fixed with a 4% paraformaldehyde solution (Affymetrix, Santa Clara, CA, USA) at room temperature for 15 min, and then stained with 0.05% Crystal violet (Fisher Scientific, Fair Lawn, NJ, USA) in distilled H 2 O for 30 min. The plates were rinsed with water and air dried. Pictures were taken using the ProteinSimple FluorChem E Imaging system. Cells were seeded in triplicate in each experiment, and the experiments were repeated three times.
Soft agar colony formation assay
Cell culture medium containing 0.7% agarose (Life Technologies) was added into six-well plates at 1.5 ml/well as the bottom layer. After the bottom layer solidified, another 1.5 ml of culture medium containing 0.4% agarose and 2 × 10 4 cells was added on top. The plates were then kept in the cell culture incubator for 3-4 weeks. Colonies were visualized and pictures were taken under an Olympus SZX9 microscope. Cells were seeded in triplicate in each experiment, and the experiments were repeated three times.
Phosphokinase array
A phosphokinase array was performed using the Proteome Profiler Human Phosphokinase Array (R&D Systems), according to the manufacturer's protocol. Stable cell lines were cultured in 10 cm tissue culture dishes until 80% confluency, and then the lysate was collected for the assay.
RARRES2 is a tumor suppressor in ACC Y Liu-Chittenden et al Immunofluorescence staining H295R cells were seeded in six-well plate at 1 × 10 6 cells/well the day before transfection. On the second day, cells were transiently transfected with 1 μg of empty vector (pCMV-XL5) or RARRES2-expressing construct (pCMV-XL5-RARRES2). Two days after transfection, the cells were trypsinized and transferred to a fresh six-well plate with cell culture medium and a glass coverslip in the well. One day later, the cells were fixed with 4% paraformaldehyde solution (Affymetrix, Cleveland, OH, USA) for 15 min and proceeded with immunofluorescent staining. Primary antibodies used were: RARRES2 antibody (5 μg/ml, Abcam, ab72965), β-catenin antibody (1:100, Cell Signaling, #8480). Secondary antibodies used were: Alexa Fluor 594 goat anti-mouse IgG (H+L) and Alexa Fluor 488 goat anti-rabbit IgG (H+L; 1:500, Life Technologies). Coverslips were mounted on slides with Vectashield mounting medium for fluorescence with DAPI (Vector Laboratories, H-1200). Images were taken using Zeiss LSM 780 confocal microscope with a × 63 objective. Three independent experiments were performed and representative images were shown.
TCF/LEF reporter assay TCF/LEF reporter assay was carried out using Cignal TCF/LEF Reporter (luc) Kit (Qiagen, CCS-018L), followed by luciferase measurement using Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA, E2920). Plate readings were measured by SpectraMax M5. Stable H295R cell lines (Vector, Line-1 and Line-2) were seeded at 5000 cells/well in 96-well in quadruplicates 1 day before transfection. On the second day, the cells were transfected with 0.1 μg of either the TCF/LEF transcription factor reporter, which contained a 40:1 mixture of inducible TCF/LEF responsive firefly luciferase reporter and constitutively expressing Renilla reporter, or the negative control, which contains a 40:1 mixture of non-inducible firefly luciferase reporter and constitutively expressing Renilla reporter. Two days after transfection, Dual-Glo luciferase assay reagent was added to each well per the manufacturer's protocol. TCF/LEF luciferase activity in each cell line was then measured as the ratio of firefly luciferase activity of the TCF/LEF reporter to the negative control. The final figure represents collective results from three independent experiments. Paired t-test was used to compare difference between each group. /SzJ (NOD scid gamma, NSG) breeder mice were purchased from The Jackson Laboratory, and were maintained and bred according to the guidelines of the National Institutes of Health Animal Research Advisory Committee (NIH-ARAC). NSG mice (five females and two males) were xenografted when they were 3-4 months old. Mice were randomly assigned to two groups, each group receiving a subcutaneous injection on both sides of the flank with 3 × 10 6 H295R cells stably expressing either RARRES2 or the control vector in a 100-μl suspension (cell culture medium: Matrigel = 1:1). A blinded measurement of the tumor size was taken each week. Tumor volumes were calculated using the equation x 2 y/2, where x is the smallest and y is the largest diameters. Mice were killed when the tumor size reached 2 cm in greatest diameter. For NSG mice, there were seven mice (14 xenografts) in each group, but one xenograft in the RAR group never developed into measurable tumor, thus was excluded from the following analysis. The animal experiments were approved by the NIH-ARAC.
Mice xenograft
Statistical analysis
All statistical analyses were performed using GraphPad Prism 6.0 (La Jolla, CA, USA). Unless otherwise specified, data are presented as mean ± s.d. Unless otherwise specified, unpaired t-tests were used to compare difference between different groups. A two-tailed P-value of o0.05 was considered statistically significant.
